Condition

Metastatic Hormone-sensitive Prostate Cancer

ClinicalTrials.gov condition label

Clinical trials14
Recruiting4
Common interventions25
Lead sponsors shown10

Clinical trials

14 shown
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.NCT07333066 · 2026-06-05
RECRUITING
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in FranceNCT07451002 · 2025-12-18
RECRUITING
An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in KoreaNCT06334120 · 2024-09-25
RECRUITING
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerNCT05818683 · 2023-04-26
RECRUITING
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT06991556 · 2025-07-07
ACTIVE_NOT_RECRUITING
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate CancerNCT07031258 · 2025-06-01
NOT_YET_RECRUITING
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical CareNCT06874114 · 2025-02-28
COMPLETED
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical CareNCT06498921 · 2024-07-15
COMPLETED
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or EnzalutamideNCT05901649 · 2023-07-05
COMPLETED
A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.NCT05059236 · 2021-11-04
COMPLETED
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) StudyNCT05381311 · 2021-09-03
COMPLETED
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerNCT03879122 · 2019-02-11
UNKNOWN
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30
COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate CancerNCT00309985 · 2006-09-26
COMPLETED

Common interventions

DocetaxelDRUG5EnzalutamideDRUG3ApalutamideDRUG2AbirateroneDRUG1Abiraterone acetate plus prednisone (AAP)DRUG1ADTOTHER1ADT (androgen deprivation therapy)DRUG1androgen-deprivation therapyDRUG1Apalutamide (Erleada™) 60 mg or 240 mg tabletsDRUG1BAY1841788 / darolutamide (ODM-201)DRUG1CabazitaxelDRUG1CetrelimabDRUG1DarolutamideDRUG1Darolutamide (BAY1841788, Nubeqa)DRUG1Darolutamide (Nubeqa, BAY1841788)DRUG1Darolutamide (Nubeqa, BAY1841788) in combination with androgen deprivation therapy (ADT) and docetaxelOTHER1Dose of docetaxelDRUG1Ipilimumab 5 MG/MLDRUG1JNJ-101556143DRUG1JSB462DRUG1Lutetium Lu-177 vipivotide tetraxetanDRUG1Nivolumab 10 MG/MLDRUG1PasritamigDRUG1PlaceboDRUG1Standard ADT (androgen deprivation therapy)DRUG1

Trial status mix

COMPLETED7
RECRUITING4
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1
UNKNOWN1

Phase mix

PHASE34
PHASE23
PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.